These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 12875416)

  • 1. Improved survival of cardiac transplantation candidates with implantable cardioverter defibrillator therapy: role of beta-blocker or amiodarone treatment.
    Ermis C; Zadeii G; Zhu AX; Fabian W; Collins J; Lurie KG; Sakaguchi S; Benditt DG
    J Cardiovasc Electrophysiol; 2003 Jun; 14(6):578-83. PubMed ID: 12875416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival benefit of the implantable cardioverter-defibrillator in patients on the waiting list for cardiac transplantation.
    Sandner SE; Wieselthaler G; Zuckermann A; Taghavi S; Schmidinger H; Pacher R; Ploner M; Laufer G; Wolner E; Grimm M
    Circulation; 2001 Sep; 104(12 Suppl 1):I171-6. PubMed ID: 11568051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A bridge, but to where?
    Sweeney MO
    J Cardiovasc Electrophysiol; 2003 Jun; 14(6):584-6. PubMed ID: 12875417
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of concomitant antiarrhythmic therapy on survival in patients with implantable cardioverter defibrillators.
    Ho AT; Pai SM; Timothy P; Pai RG
    Pacing Clin Electrophysiol; 2005 Jul; 28(7):647-53. PubMed ID: 16008799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implantable cardioverter-defibrillators in end-stage heart failure patients listed for heart transplantation: Results from a large retrospective registry.
    Gandjbakhch E; Rovani M; Varnous S; Maupain C; Chastre T; Waintraub X; Pousset F; Lebreton G; Duthoit G; Badenco N; Himbert C; Leprince P; Hidden-Lucet F
    Arch Cardiovasc Dis; 2016; 109(8-9):476-85. PubMed ID: 27344378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Strategies in management of heart transplantation candidates with tachycardic ventricular arrhythmia anamnesis].
    Grimm M; Grimm G; Zuckermann A; Wieselthaler G; Daneschvar H; Kocher A; Feuerstein M; Schmidinger H; Podczeck A; Pacher R
    Wien Klin Wochenschr; 1995; 107(16):479-84. PubMed ID: 7571641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implantable cardioverter-defibrillators for treatment of sustained ventricular arrhythmias in patients with Chagas' heart disease: comparison with a control group treated with amiodarone alone.
    Gali WL; Sarabanda AV; Baggio JM; Ferreira LG; Gomes GG; Marin-Neto JA; Junqueira LF
    Europace; 2014 May; 16(5):674-80. PubMed ID: 24481778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylactic implantable cardioverter defibrillator treatment in patients with end-stage heart failure awaiting heart transplantation.
    Fröhlich GM; Holzmeister J; Hübler M; Hübler S; Wolfrum M; Enseleit F; Seifert B; Hürlimann D; Lehmkuhl HB; Noll G; Steffel J; Falk V; Lüscher TF; Hetzer R; Ruschitzka F
    Heart; 2013 Aug; 99(16):1158-65. PubMed ID: 23813845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of implantable cardioverter-defibrillators on mortality among patients on the waiting list for heart transplantation.
    Grimm M; Wieselthaler G; Avanessian R; Grimm G; Schmidinger H; Schreiner W; Podczeck A; Wolner E; Laufer G
    J Thorac Cardiovasc Surg; 1995 Aug; 110(2):532-9. PubMed ID: 7637372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival of antiarrhythmic or implantable cardioverter defibrillator treated patients with varying degrees of left ventricular dysfunction who survived malignant ventricular arrhythmias.
    Domanski MJ; Epstein A; Hallstrom A; Saksena S; Zipes DP
    J Cardiovasc Electrophysiol; 2002 Jun; 13(6):580-3. PubMed ID: 12108501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial.
    Wilkoff BL; Cook JR; Epstein AE; Greene HL; Hallstrom AP; Hsia H; Kutalek SP; Sharma A;
    JAMA; 2002 Dec; 288(24):3115-23. PubMed ID: 12495391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of implantable cardioverter-defibrillators in patients with continuous flow left ventricular assist devices.
    Enriquez AD; Calenda B; Miller MA; Anyanwu AC; Pinney SP
    Circ Arrhythm Electrophysiol; 2013 Aug; 6(4):668-74. PubMed ID: 23873139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amiodarone therapy in patients implanted with cardioverter-defibrillator for life-threatening ventricular arrhythmias.
    Satomi K; Kurita T; Takatsuki S; Yokoyama Y; Chinushi M; Tsuboi N; Nitta T; Shoda M; Mitamura H
    Circ J; 2006 Aug; 70(8):977-84. PubMed ID: 16864928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mortality benefit of implantable cardioverter-defibrillator therapy in patients with persistent malignant ventricular arrhythmias despite amiodarone treatment.
    Barron HV; Khan HH; Viskin S; Heller K; Kalman JM; Scheinman MM; Lesh MD
    Am J Cardiol; 1997 May; 79(9):1180-4. PubMed ID: 9164881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.
    Connolly SJ; Dorian P; Roberts RS; Gent M; Bailin S; Fain ES; Thorpe K; Champagne J; Talajic M; Coutu B; Gronefeld GC; Hohnloser SH;
    JAMA; 2006 Jan; 295(2):165-71. PubMed ID: 16403928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of the implantable cardioverter/defibrillator on sudden death and total mortality in patients evaluated for cardiac transplantation.
    Sweeney MO; Ruskin JN; Garan H; McGovern BA; Guy ML; Torchiana DF; Vlahakes GJ; Newell JB; Semigran MJ; Dec GW
    Circulation; 1995 Dec; 92(11):3273-81. PubMed ID: 7586314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ICD therapy in survivors of sudden cardiac death awaiting heart transplantation.
    Grimm M; Grimm G; Zuckermann A; Wieselthaler G; Feuerstein M; Daneschvar H; Schmiedinger H; Schreiner W; Wolner E; Laufer G
    Ann Thorac Surg; 1995 Apr; 59(4):916-20. PubMed ID: 7695418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction.
    Sanders GD; Hlatky MA; Every NR; McDonald KM; Heidenreich PA; Parsons LS; Owens DK
    Ann Intern Med; 2001 Nov; 135(10):870-83. PubMed ID: 11712877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiarrhythmic drugs in patients with implantable cardioverter-defibrillators.
    Bollmann A; Husser D; Cannom DS
    Am J Cardiovasc Drugs; 2005; 5(6):371-8. PubMed ID: 16259525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies.
    Baquero GA; Banchs JE; Depalma S; Young SK; Penny-Peterson ED; Samii SM; Wolbrette DL; Naccarelli GV; Gonzalez MD
    J Cardiovasc Electrophysiol; 2012 Mar; 23(3):296-301. PubMed ID: 21955243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.